These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

286 related articles for article (PubMed ID: 17319455)

  • 1. A review of Perindopril in the reduction of cardiovascular events.
    Campbell DJ
    Vasc Health Risk Manag; 2006; 2(2):117-24. PubMed ID: 17319455
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Perindopril for the treatment of hypertension.
    Ghiadoni L
    Expert Opin Pharmacother; 2011 Jul; 12(10):1633-42. PubMed ID: 21599567
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trial-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial.
    Dahlöf B; Sever PS; Poulter NR; Wedel H; Beevers DG; Caulfield M; Collins R; Kjeldsen SE; Kristinsson A; McInnes GT; Mehlsen J; Nieminen M; O'Brien E; Ostergren J;
    Lancet; 2005 Sep 10-16; 366(9489):895-906. PubMed ID: 16154016
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The ASCOT trial: clarifying the role of ACE inhibition in the reduction of cardiovascular events in patients with hypertension.
    Meurin P
    Am J Cardiovasc Drugs; 2006; 6(5):327-34. PubMed ID: 17083267
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Angiotensin-converting enzyme inhibition in cardiovascular disease: evidence with perindopril.
    Ferrari R
    Expert Rev Cardiovasc Ther; 2005 Jan; 3(1):15-29. PubMed ID: 15723572
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Hypertension, heart failure, myocardial infarction, secondary prevention: the role of perindopril].
    Rapezzi C; Ciliberti P; Graziosi M; Riva L
    Ital Heart J; 2005 Nov; 6 Suppl 7():40S-47S. PubMed ID: 16485516
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reduced blood pressure variability in ASCOT-BPLA trial favours use of amlodipine/perindopril combination to reduce stroke risk.
    Aalbers J
    Cardiovasc J Afr; 2010; 21(2):115. PubMed ID: 20532438
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Perindopril/indapamide combination in the first-line treatment of hypertension and end-organ protection.
    Gosse P
    Expert Rev Cardiovasc Ther; 2006 May; 4(3):319-33. PubMed ID: 16716093
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Perindopril: a review of its use in patients with or at risk of developing coronary artery disease.
    Curran MP; McCormack PL; Simpson D
    Drugs; 2006; 66(2):235-55. PubMed ID: 16451098
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Perindopril-based blood pressure-lowering reduces major vascular events in patients with atrial fibrillation and prior stroke or transient ischemic attack.
    Arima H; Hart RG; Colman S; Chalmers J; Anderson C; Rodgers A; Woodward M; MacMahon S; Neal B;
    Stroke; 2005 Oct; 36(10):2164-9. PubMed ID: 16141420
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Are angiotensin-converting enzyme inhibitors and angiotensin receptor blockers especially useful for cardiovascular protection?
    Ong HT
    J Am Board Fam Med; 2009; 22(6):686-97. PubMed ID: 19897698
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Specific properties and effect of perindopril in controlling the renin-angiotensin system.
    Ferrari R; Pasanisi G; Notarstefano P; Campo G; Gardini E; Ceconi C
    Am J Hypertens; 2005 Sep; 18(9 Pt 2):142S-154S. PubMed ID: 16125051
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Blood pressure lowering, not vascular mechanism of action, is the primary determinant of clinical outcome.
    Leenen FH
    Can J Cardiol; 2004 Aug; 20 Suppl B():77B-82B. PubMed ID: 15309209
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of blood pressure lowering with perindopril and indapamide therapy on dementia and cognitive decline in patients with cerebrovascular disease.
    Tzourio C; Anderson C; Chapman N; Woodward M; Neal B; MacMahon S; Chalmers J;
    Arch Intern Med; 2003 May; 163(9):1069-75. PubMed ID: 12742805
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Perindopril for control of blood pressure in patients with hypertension and other cardiovascular risk factors: an open-label, observational, multicentre, general practice-based study.
    Ogilvie RI; Anand S; Roy P; De Souza S;
    Clin Drug Investig; 2008; 28(11):673-86. PubMed ID: 18840010
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The EUROPA trial.
    Kwaku M; Burman KD; Becker KL; Mannan M
    Lancet; 2003 Dec; 362(9399):1935; author reply 1936-7. PubMed ID: 14667758
    [No Abstract]   [Full Text] [Related]  

  • 17. Blocking the renin-angiotensin-aldosterone system or lowering the blood pressure: does EUROPA help?
    Mackay JA
    J Renin Angiotensin Aldosterone Syst; 2003 Dec; 4(4):205-6. PubMed ID: 14689366
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of treatment of hypertensive patients with fixed combination perindopril/indapamide up to 10/2.5 mg: results of the FALCO FORTE programme.
    Pella D
    High Blood Press Cardiovasc Prev; 2011 Sep; 18(3):107-13. PubMed ID: 21950782
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of perindopril in reduction of cardiovascular events among patients with stable coronary artery disease: randomised, double-blind, placebo-controlled, multicentre trial (the EUROPA study).
    Fox KM;
    Lancet; 2003 Sep; 362(9386):782-8. PubMed ID: 13678872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combination therapy in the extended cardiovascular continuum: a focus on perindopril and amlodipine.
    Borghi C; Morbini M; Cicero AF
    J Cardiovasc Med (Hagerstown); 2015 May; 16(5):390-9. PubMed ID: 25590639
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.